nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Bronchial hyperreactivity—Naltrexone—alcohol dependence	0.0285	0.0399	CcSEcCtD
Regadenoson—Chronic obstructive pulmonary disease—Naltrexone—alcohol dependence	0.026	0.0365	CcSEcCtD
Regadenoson—Peripheral coldness—Naltrexone—alcohol dependence	0.0156	0.0219	CcSEcCtD
Regadenoson—ADORA2A—forebrain—alcohol dependence	0.015	0.144	CbGeAlD
Regadenoson—Pain in jaw—Citalopram—alcohol dependence	0.0145	0.0203	CcSEcCtD
Regadenoson—Eye pain—Disulfiram—alcohol dependence	0.0128	0.018	CcSEcCtD
Regadenoson—ADORA2A—cardiovascular system—alcohol dependence	0.0126	0.122	CbGeAlD
Regadenoson—ADORA2A—gonad—alcohol dependence	0.0115	0.111	CbGeAlD
Regadenoson—ADORA2A—Monoamine Transport—SLC6A4—alcohol dependence	0.0106	0.0581	CbGpPWpGaD
Regadenoson—ADORA2A—blood—alcohol dependence	0.01	0.0965	CbGeAlD
Regadenoson—Peripheral coldness—Citalopram—alcohol dependence	0.0099	0.0139	CcSEcCtD
Regadenoson—Sinus bradycardia—Citalopram—alcohol dependence	0.00961	0.0135	CcSEcCtD
Regadenoson—Throat tightness—Citalopram—alcohol dependence	0.00961	0.0135	CcSEcCtD
Regadenoson—Abdominal discomfort—Disulfiram—alcohol dependence	0.0096	0.0135	CcSEcCtD
Regadenoson—ADORA2A—Monoamine Transport—SLC6A3—alcohol dependence	0.00946	0.0518	CbGpPWpGaD
Regadenoson—Transient ischaemic attack—Citalopram—alcohol dependence	0.00934	0.0131	CcSEcCtD
Regadenoson—Throat irritation—Citalopram—alcohol dependence	0.00934	0.0131	CcSEcCtD
Regadenoson—Injection site pain—Naltrexone—alcohol dependence	0.00911	0.0128	CcSEcCtD
Regadenoson—ADORA2A—endocrine gland—alcohol dependence	0.00867	0.0837	CbGeAlD
Regadenoson—Chest discomfort—Naltrexone—alcohol dependence	0.00841	0.0118	CcSEcCtD
Regadenoson—ADORA2A—testis—alcohol dependence	0.00827	0.0798	CbGeAlD
Regadenoson—ADORA2A—nervous system—alcohol dependence	0.00812	0.0783	CbGeAlD
Regadenoson—Hypoaesthesia—Disulfiram—alcohol dependence	0.00797	0.0112	CcSEcCtD
Regadenoson—ADORA2A—liver—alcohol dependence	0.00782	0.0755	CbGeAlD
Regadenoson—ADORA2A—central nervous system—alcohol dependence	0.00782	0.0754	CbGeAlD
Regadenoson—ADORA2A—cerebellum—alcohol dependence	0.00764	0.0737	CbGeAlD
Regadenoson—Electrocardiogram QT prolonged—Citalopram—alcohol dependence	0.00734	0.0103	CcSEcCtD
Regadenoson—Ventricular arrhythmia—Citalopram—alcohol dependence	0.00637	0.00893	CcSEcCtD
Regadenoson—ADORA2A—brain—alcohol dependence	0.00621	0.0599	CbGeAlD
Regadenoson—ADORA2A—GPCRs, Other—CHRM2—alcohol dependence	0.00607	0.0332	CbGpPWpGaD
Regadenoson—Feeling hot—Citalopram—alcohol dependence	0.006	0.00842	CcSEcCtD
Regadenoson—Myocardial ischaemia—Citalopram—alcohol dependence	0.00586	0.00822	CcSEcCtD
Regadenoson—Atrial fibrillation—Naltrexone—alcohol dependence	0.0057	0.00799	CcSEcCtD
Regadenoson—Pallor—Citalopram—alcohol dependence	0.00569	0.00797	CcSEcCtD
Regadenoson—Extrasystoles—Citalopram—alcohol dependence	0.0056	0.00785	CcSEcCtD
Regadenoson—Pain in extremity—Naltrexone—alcohol dependence	0.0054	0.00757	CcSEcCtD
Regadenoson—Chest discomfort—Citalopram—alcohol dependence	0.00533	0.00747	CcSEcCtD
Regadenoson—Paraesthesia—Disulfiram—alcohol dependence	0.00511	0.00717	CcSEcCtD
Regadenoson—Somnolence—Disulfiram—alcohol dependence	0.00506	0.0071	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—CRHR1—alcohol dependence	0.00504	0.0276	CbGpPWpGaD
Regadenoson—Abdominal distension—Acamprosate—alcohol dependence	0.00497	0.00696	CcSEcCtD
Regadenoson—Asthma—Acamprosate—alcohol dependence	0.00493	0.00691	CcSEcCtD
Regadenoson—Pain—Disulfiram—alcohol dependence	0.00487	0.00683	CcSEcCtD
Regadenoson—Angina pectoris—Acamprosate—alcohol dependence	0.0048	0.00674	CcSEcCtD
Regadenoson—Musculoskeletal pain—Citalopram—alcohol dependence	0.00477	0.00669	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—OPRK1—alcohol dependence	0.00468	0.0256	CbGpPWpGaD
Regadenoson—Wheezing—Citalopram—alcohol dependence	0.00458	0.00642	CcSEcCtD
Regadenoson—Depressed level of consciousness—Citalopram—alcohol dependence	0.00455	0.00638	CcSEcCtD
Regadenoson—Angina pectoris—Naltrexone—alcohol dependence	0.00455	0.00637	CcSEcCtD
Regadenoson—Abdominal discomfort—Naltrexone—alcohol dependence	0.00447	0.00627	CcSEcCtD
Regadenoson—Acute coronary syndrome—Acamprosate—alcohol dependence	0.00434	0.00608	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Other—DRD4—alcohol dependence	0.00432	0.0237	CbGpPWpGaD
Regadenoson—Myocardial infarction—Acamprosate—alcohol dependence	0.00431	0.00604	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Other—CNR1—alcohol dependence	0.00413	0.0226	CbGpPWpGaD
Regadenoson—Acute coronary syndrome—Naltrexone—alcohol dependence	0.0041	0.00575	CcSEcCtD
Regadenoson—Asthenia—Disulfiram—alcohol dependence	0.00409	0.00573	CcSEcCtD
Regadenoson—Myocardial infarction—Naltrexone—alcohol dependence	0.00408	0.00572	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Other—HTR7—alcohol dependence	0.00403	0.022	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—OPRK1—alcohol dependence	0.00401	0.0219	CbGpPWpGaD
Regadenoson—Hypoaesthesia—Acamprosate—alcohol dependence	0.00393	0.00551	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—CRH—alcohol dependence	0.00386	0.0211	CbGpPWpGaD
Regadenoson—Eye pain—Citalopram—alcohol dependence	0.00379	0.00531	CcSEcCtD
Regadenoson—Dizziness—Disulfiram—alcohol dependence	0.00377	0.00528	CcSEcCtD
Regadenoson—Tinnitus—Acamprosate—alcohol dependence	0.00368	0.00516	CcSEcCtD
Regadenoson—Connective tissue disorder—Naltrexone—alcohol dependence	0.00367	0.00515	CcSEcCtD
Regadenoson—Atrial fibrillation—Citalopram—alcohol dependence	0.00361	0.00506	CcSEcCtD
Regadenoson—Rash—Disulfiram—alcohol dependence	0.00359	0.00503	CcSEcCtD
Regadenoson—Headache—Disulfiram—alcohol dependence	0.00357	0.005	CcSEcCtD
Regadenoson—Immune system disorder—Acamprosate—alcohol dependence	0.00357	0.005	CcSEcCtD
Regadenoson—Cerebrovascular accident—Citalopram—alcohol dependence	0.00349	0.00489	CcSEcCtD
Regadenoson—Eye disorder—Naltrexone—alcohol dependence	0.00349	0.00489	CcSEcCtD
Regadenoson—Tinnitus—Naltrexone—alcohol dependence	0.00348	0.00488	CcSEcCtD
Regadenoson—Cardiac disorder—Naltrexone—alcohol dependence	0.00347	0.00486	CcSEcCtD
Regadenoson—Mental disorder—Acamprosate—alcohol dependence	0.00346	0.00485	CcSEcCtD
Regadenoson—Pain in extremity—Citalopram—alcohol dependence	0.00342	0.0048	CcSEcCtD
Regadenoson—Angiopathy—Naltrexone—alcohol dependence	0.00339	0.00475	CcSEcCtD
Regadenoson—Immune system disorder—Naltrexone—alcohol dependence	0.00337	0.00473	CcSEcCtD
Regadenoson—Mediastinal disorder—Naltrexone—alcohol dependence	0.00337	0.00472	CcSEcCtD
Regadenoson—Dysgeusia—Acamprosate—alcohol dependence	0.00337	0.00472	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—EP300—alcohol dependence	0.00328	0.018	CbGpPWpGaD
Regadenoson—Mental disorder—Naltrexone—alcohol dependence	0.00327	0.00459	CcSEcCtD
Regadenoson—Cardiac arrest—Citalopram—alcohol dependence	0.00325	0.00456	CcSEcCtD
Regadenoson—Tremor—Acamprosate—alcohol dependence	0.00322	0.00451	CcSEcCtD
Regadenoson—Ill-defined disorder—Acamprosate—alcohol dependence	0.00319	0.00447	CcSEcCtD
Regadenoson—Dysgeusia—Naltrexone—alcohol dependence	0.00318	0.00446	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—OPRD1—alcohol dependence	0.00315	0.0172	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—HTR7—alcohol dependence	0.00314	0.0172	CbGpPWpGaD
Regadenoson—Angioedema—Acamprosate—alcohol dependence	0.00314	0.0044	CcSEcCtD
Regadenoson—Malaise—Acamprosate—alcohol dependence	0.0031	0.00434	CcSEcCtD
Regadenoson—Syncope—Acamprosate—alcohol dependence	0.00308	0.00432	CcSEcCtD
Regadenoson—Vision blurred—Naltrexone—alcohol dependence	0.00306	0.0043	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—OPRK1—alcohol dependence	0.00305	0.0167	CbGpPWpGaD
Regadenoson—Tremor—Naltrexone—alcohol dependence	0.00305	0.00427	CcSEcCtD
Regadenoson—Palpitations—Acamprosate—alcohol dependence	0.00304	0.00426	CcSEcCtD
Regadenoson—Loss of consciousness—Acamprosate—alcohol dependence	0.00302	0.00423	CcSEcCtD
Regadenoson—Ill-defined disorder—Naltrexone—alcohol dependence	0.00302	0.00423	CcSEcCtD
Regadenoson—Cough—Acamprosate—alcohol dependence	0.003	0.0042	CcSEcCtD
Regadenoson—Convulsion—Acamprosate—alcohol dependence	0.00298	0.00417	CcSEcCtD
Regadenoson—Abdominal distension—Citalopram—alcohol dependence	0.00298	0.00417	CcSEcCtD
Regadenoson—Angioedema—Naltrexone—alcohol dependence	0.00297	0.00416	CcSEcCtD
Regadenoson—Hypertension—Acamprosate—alcohol dependence	0.00297	0.00416	CcSEcCtD
Regadenoson—Asthma—Citalopram—alcohol dependence	0.00296	0.00414	CcSEcCtD
Regadenoson—Malaise—Naltrexone—alcohol dependence	0.00293	0.00411	CcSEcCtD
Regadenoson—Myalgia—Acamprosate—alcohol dependence	0.00293	0.0041	CcSEcCtD
Regadenoson—Chest pain—Acamprosate—alcohol dependence	0.00293	0.0041	CcSEcCtD
Regadenoson—Arthralgia—Acamprosate—alcohol dependence	0.00293	0.0041	CcSEcCtD
Regadenoson—Syncope—Naltrexone—alcohol dependence	0.00292	0.00409	CcSEcCtD
Regadenoson—Anxiety—Acamprosate—alcohol dependence	0.00292	0.00409	CcSEcCtD
Regadenoson—Bronchospasm—Citalopram—alcohol dependence	0.00291	0.00408	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Acamprosate—alcohol dependence	0.00291	0.00407	CcSEcCtD
Regadenoson—Discomfort—Acamprosate—alcohol dependence	0.00289	0.00405	CcSEcCtD
Regadenoson—Angina pectoris—Citalopram—alcohol dependence	0.00288	0.00404	CcSEcCtD
Regadenoson—Palpitations—Naltrexone—alcohol dependence	0.00287	0.00403	CcSEcCtD
Regadenoson—Loss of consciousness—Naltrexone—alcohol dependence	0.00286	0.00401	CcSEcCtD
Regadenoson—Cough—Naltrexone—alcohol dependence	0.00284	0.00398	CcSEcCtD
Regadenoson—Abdominal discomfort—Citalopram—alcohol dependence	0.00283	0.00397	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Other—HTR2A—alcohol dependence	0.00282	0.0154	CbGpPWpGaD
Regadenoson—Convulsion—Naltrexone—alcohol dependence	0.00282	0.00395	CcSEcCtD
Regadenoson—Hypertension—Naltrexone—alcohol dependence	0.00281	0.00394	CcSEcCtD
Regadenoson—Anaphylactic shock—Acamprosate—alcohol dependence	0.0028	0.00393	CcSEcCtD
Regadenoson—Chest pain—Naltrexone—alcohol dependence	0.00277	0.00388	CcSEcCtD
Regadenoson—Myalgia—Naltrexone—alcohol dependence	0.00277	0.00388	CcSEcCtD
Regadenoson—Arthralgia—Naltrexone—alcohol dependence	0.00277	0.00388	CcSEcCtD
Regadenoson—Shock—Acamprosate—alcohol dependence	0.00276	0.00387	CcSEcCtD
Regadenoson—Anxiety—Naltrexone—alcohol dependence	0.00276	0.00387	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Naltrexone—alcohol dependence	0.00275	0.00385	CcSEcCtD
Regadenoson—Tachycardia—Acamprosate—alcohol dependence	0.00274	0.00384	CcSEcCtD
Regadenoson—Discomfort—Naltrexone—alcohol dependence	0.00274	0.00383	CcSEcCtD
Regadenoson—Skin disorder—Acamprosate—alcohol dependence	0.00272	0.00382	CcSEcCtD
Regadenoson—Hyperhidrosis—Acamprosate—alcohol dependence	0.00271	0.0038	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—OPRD1—alcohol dependence	0.0027	0.0147	CbGpPWpGaD
Regadenoson—Anaphylactic shock—Naltrexone—alcohol dependence	0.00265	0.00372	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—AVP—alcohol dependence	0.00265	0.0145	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CHRM2—alcohol dependence	0.00264	0.0144	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—CRH—alcohol dependence	0.00262	0.0144	CbGpPWpGaD
Regadenoson—Hypotension—Acamprosate—alcohol dependence	0.00262	0.00367	CcSEcCtD
Regadenoson—Shock—Naltrexone—alcohol dependence	0.00261	0.00366	CcSEcCtD
Regadenoson—Nervous system disorder—Naltrexone—alcohol dependence	0.0026	0.00365	CcSEcCtD
Regadenoson—Acute coronary syndrome—Citalopram—alcohol dependence	0.0026	0.00364	CcSEcCtD
Regadenoson—Tachycardia—Naltrexone—alcohol dependence	0.00259	0.00363	CcSEcCtD
Regadenoson—Myocardial infarction—Citalopram—alcohol dependence	0.00258	0.00362	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—PDYN—alcohol dependence	0.00258	0.0141	CbGpPWpGaD
Regadenoson—Skin disorder—Naltrexone—alcohol dependence	0.00258	0.00361	CcSEcCtD
Regadenoson—Hyperhidrosis—Naltrexone—alcohol dependence	0.00257	0.0036	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Acamprosate—alcohol dependence	0.00256	0.00358	CcSEcCtD
Regadenoson—Insomnia—Acamprosate—alcohol dependence	0.00254	0.00356	CcSEcCtD
Regadenoson—Paraesthesia—Acamprosate—alcohol dependence	0.00252	0.00353	CcSEcCtD
Regadenoson—Dyspnoea—Acamprosate—alcohol dependence	0.0025	0.00351	CcSEcCtD
Regadenoson—Somnolence—Acamprosate—alcohol dependence	0.00249	0.0035	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—SLC6A4—alcohol dependence	0.00244	0.0133	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Acamprosate—alcohol dependence	0.00242	0.00339	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—OPRM1—alcohol dependence	0.00242	0.0132	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Naltrexone—alcohol dependence	0.00242	0.00339	CcSEcCtD
Regadenoson—Bradycardia—Citalopram—alcohol dependence	0.00241	0.00338	CcSEcCtD
Regadenoson—Insomnia—Naltrexone—alcohol dependence	0.0024	0.00336	CcSEcCtD
Regadenoson—Pain—Acamprosate—alcohol dependence	0.0024	0.00336	CcSEcCtD
Regadenoson—Paraesthesia—Naltrexone—alcohol dependence	0.00238	0.00334	CcSEcCtD
Regadenoson—Dyspnoea—Naltrexone—alcohol dependence	0.00237	0.00332	CcSEcCtD
Regadenoson—Somnolence—Naltrexone—alcohol dependence	0.00236	0.00331	CcSEcCtD
Regadenoson—Hypoaesthesia—Citalopram—alcohol dependence	0.00235	0.0033	CcSEcCtD
Regadenoson—Connective tissue disorder—Citalopram—alcohol dependence	0.00233	0.00326	CcSEcCtD
Regadenoson—Feeling abnormal—Acamprosate—alcohol dependence	0.00231	0.00324	CcSEcCtD
Regadenoson—Gastrointestinal pain—Acamprosate—alcohol dependence	0.00229	0.00322	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—DRD4—alcohol dependence	0.00229	0.0126	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Naltrexone—alcohol dependence	0.00229	0.00321	CcSEcCtD
Regadenoson—Pain—Naltrexone—alcohol dependence	0.00227	0.00318	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CHRM2—alcohol dependence	0.00226	0.0124	CbGpPWpGaD
Regadenoson—Urticaria—Acamprosate—alcohol dependence	0.00223	0.00312	CcSEcCtD
Regadenoson—Abdominal pain—Acamprosate—alcohol dependence	0.00222	0.00311	CcSEcCtD
Regadenoson—Eye disorder—Citalopram—alcohol dependence	0.00221	0.0031	CcSEcCtD
Regadenoson—Tinnitus—Citalopram—alcohol dependence	0.00221	0.00309	CcSEcCtD
Regadenoson—Cardiac disorder—Citalopram—alcohol dependence	0.0022	0.00308	CcSEcCtD
Regadenoson—Flushing—Citalopram—alcohol dependence	0.0022	0.00308	CcSEcCtD
Regadenoson—Feeling abnormal—Naltrexone—alcohol dependence	0.00219	0.00307	CcSEcCtD
Regadenoson—Gastrointestinal pain—Naltrexone—alcohol dependence	0.00217	0.00304	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—HTR1B—alcohol dependence	0.00215	0.0118	CbGpPWpGaD
Regadenoson—Angiopathy—Citalopram—alcohol dependence	0.00215	0.00301	CcSEcCtD
Regadenoson—Immune system disorder—Citalopram—alcohol dependence	0.00214	0.003	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—DRD2—alcohol dependence	0.00214	0.0117	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—HTR7—alcohol dependence	0.00214	0.0117	CbGpPWpGaD
Regadenoson—Mediastinal disorder—Citalopram—alcohol dependence	0.00213	0.00299	CcSEcCtD
Regadenoson—Urticaria—Naltrexone—alcohol dependence	0.00211	0.00296	CcSEcCtD
Regadenoson—Abdominal pain—Naltrexone—alcohol dependence	0.0021	0.00294	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—alcohol dependence	0.00207	0.0113	CbGpPWpGaD
Regadenoson—Mental disorder—Citalopram—alcohol dependence	0.00207	0.00291	CcSEcCtD
Regadenoson—Hypersensitivity—Acamprosate—alcohol dependence	0.00207	0.0029	CcSEcCtD
Regadenoson—Erythema—Citalopram—alcohol dependence	0.00206	0.00289	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—OPRD1—alcohol dependence	0.00205	0.0112	CbGpPWpGaD
Regadenoson—Dysgeusia—Citalopram—alcohol dependence	0.00202	0.00283	CcSEcCtD
Regadenoson—Asthenia—Acamprosate—alcohol dependence	0.00201	0.00282	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—PDYN—alcohol dependence	0.00197	0.0108	CbGpPWpGaD
Regadenoson—Hypersensitivity—Naltrexone—alcohol dependence	0.00196	0.00274	CcSEcCtD
Regadenoson—Vision blurred—Citalopram—alcohol dependence	0.00194	0.00272	CcSEcCtD
Regadenoson—Tremor—Citalopram—alcohol dependence	0.00193	0.00271	CcSEcCtD
Regadenoson—Diarrhoea—Acamprosate—alcohol dependence	0.00192	0.00269	CcSEcCtD
Regadenoson—Ill-defined disorder—Citalopram—alcohol dependence	0.00191	0.00268	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—NPY—alcohol dependence	0.00191	0.0104	CbGpPWpGaD
Regadenoson—Asthenia—Naltrexone—alcohol dependence	0.0019	0.00267	CcSEcCtD
Regadenoson—Angioedema—Citalopram—alcohol dependence	0.00188	0.00264	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—DRD4—alcohol dependence	0.00188	0.0103	CbGpPWpGaD
Regadenoson—Malaise—Citalopram—alcohol dependence	0.00186	0.0026	CcSEcCtD
Regadenoson—Dizziness—Acamprosate—alcohol dependence	0.00185	0.0026	CcSEcCtD
Regadenoson—Syncope—Citalopram—alcohol dependence	0.00185	0.00259	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—alcohol dependence	0.00184	0.0101	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CRHR1—alcohol dependence	0.00183	0.01	CbGpPWpGaD
Regadenoson—Palpitations—Citalopram—alcohol dependence	0.00182	0.00255	CcSEcCtD
Regadenoson—Diarrhoea—Naltrexone—alcohol dependence	0.00182	0.00255	CcSEcCtD
Regadenoson—Loss of consciousness—Citalopram—alcohol dependence	0.00181	0.00254	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—AVP—alcohol dependence	0.0018	0.00984	CbGpPWpGaD
Regadenoson—Cough—Citalopram—alcohol dependence	0.0018	0.00252	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CNR1—alcohol dependence	0.00179	0.00981	CbGpPWpGaD
Regadenoson—Convulsion—Citalopram—alcohol dependence	0.00179	0.0025	CcSEcCtD
Regadenoson—Vomiting—Acamprosate—alcohol dependence	0.00178	0.0025	CcSEcCtD
Regadenoson—Hypertension—Citalopram—alcohol dependence	0.00178	0.00249	CcSEcCtD
Regadenoson—Rash—Acamprosate—alcohol dependence	0.00177	0.00248	CcSEcCtD
Regadenoson—Dermatitis—Acamprosate—alcohol dependence	0.00177	0.00248	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—POMC—alcohol dependence	0.00176	0.00963	CbGpPWpGaD
Regadenoson—Headache—Acamprosate—alcohol dependence	0.00176	0.00246	CcSEcCtD
Regadenoson—Dizziness—Naltrexone—alcohol dependence	0.00175	0.00246	CcSEcCtD
Regadenoson—Myalgia—Citalopram—alcohol dependence	0.00175	0.00246	CcSEcCtD
Regadenoson—Arthralgia—Citalopram—alcohol dependence	0.00175	0.00246	CcSEcCtD
Regadenoson—Chest pain—Citalopram—alcohol dependence	0.00175	0.00246	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—DRD2—alcohol dependence	0.00175	0.00958	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—HTR7—alcohol dependence	0.00175	0.00958	CbGpPWpGaD
Regadenoson—Anxiety—Citalopram—alcohol dependence	0.00175	0.00245	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Citalopram—alcohol dependence	0.00174	0.00244	CcSEcCtD
Regadenoson—Discomfort—Citalopram—alcohol dependence	0.00173	0.00243	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—OPRK1—alcohol dependence	0.00173	0.00944	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CHRM2—alcohol dependence	0.00172	0.00941	CbGpPWpGaD
Regadenoson—Vomiting—Naltrexone—alcohol dependence	0.00169	0.00237	CcSEcCtD
Regadenoson—Anaphylactic shock—Citalopram—alcohol dependence	0.00168	0.00236	CcSEcCtD
Regadenoson—Rash—Naltrexone—alcohol dependence	0.00167	0.00235	CcSEcCtD
Regadenoson—Dermatitis—Naltrexone—alcohol dependence	0.00167	0.00234	CcSEcCtD
Regadenoson—Nausea—Acamprosate—alcohol dependence	0.00167	0.00234	CcSEcCtD
Regadenoson—Headache—Naltrexone—alcohol dependence	0.00166	0.00233	CcSEcCtD
Regadenoson—Shock—Citalopram—alcohol dependence	0.00165	0.00232	CcSEcCtD
Regadenoson—Nervous system disorder—Citalopram—alcohol dependence	0.00165	0.00231	CcSEcCtD
Regadenoson—Tachycardia—Citalopram—alcohol dependence	0.00164	0.0023	CcSEcCtD
Regadenoson—Skin disorder—Citalopram—alcohol dependence	0.00163	0.00229	CcSEcCtD
Regadenoson—Hyperhidrosis—Citalopram—alcohol dependence	0.00163	0.00228	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—alcohol dependence	0.00161	0.00881	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—OPRM1—alcohol dependence	0.00158	0.00864	CbGpPWpGaD
Regadenoson—Nausea—Naltrexone—alcohol dependence	0.00158	0.00221	CcSEcCtD
Regadenoson—Hypotension—Citalopram—alcohol dependence	0.00157	0.0022	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—OPRK1—alcohol dependence	0.00157	0.00858	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CNR1—alcohol dependence	0.00154	0.00841	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Citalopram—alcohol dependence	0.00153	0.00215	CcSEcCtD
Regadenoson—Insomnia—Citalopram—alcohol dependence	0.00152	0.00213	CcSEcCtD
Regadenoson—Paraesthesia—Citalopram—alcohol dependence	0.00151	0.00212	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—alcohol dependence	0.0015	0.0082	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HTR7—alcohol dependence	0.0015	0.0082	CbGpPWpGaD
Regadenoson—Dyspnoea—Citalopram—alcohol dependence	0.0015	0.0021	CcSEcCtD
Regadenoson—Somnolence—Citalopram—alcohol dependence	0.00149	0.0021	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—NPY—alcohol dependence	0.00145	0.00795	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Citalopram—alcohol dependence	0.00145	0.00203	CcSEcCtD
Regadenoson—Pain—Citalopram—alcohol dependence	0.00144	0.00202	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—CRH—alcohol dependence	0.0014	0.00767	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—HTR1B—alcohol dependence	0.0014	0.00767	CbGpPWpGaD
Regadenoson—Feeling abnormal—Citalopram—alcohol dependence	0.00139	0.00194	CcSEcCtD
Regadenoson—Gastrointestinal pain—Citalopram—alcohol dependence	0.00137	0.00193	CcSEcCtD
Regadenoson—Urticaria—Citalopram—alcohol dependence	0.00134	0.00187	CcSEcCtD
Regadenoson—Abdominal pain—Citalopram—alcohol dependence	0.00133	0.00186	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AVP—alcohol dependence	0.00126	0.00691	CbGpPWpGaD
Regadenoson—Hypersensitivity—Citalopram—alcohol dependence	0.00124	0.00174	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—HTR2A—alcohol dependence	0.00123	0.00671	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—DRD4—alcohol dependence	0.00123	0.00671	CbGpPWpGaD
Regadenoson—Asthenia—Citalopram—alcohol dependence	0.00121	0.00169	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—CNR1—alcohol dependence	0.00117	0.0064	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—OPRD1—alcohol dependence	0.00116	0.00635	CbGpPWpGaD
Regadenoson—Diarrhoea—Citalopram—alcohol dependence	0.00115	0.00161	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—HTR7—alcohol dependence	0.00114	0.00625	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—DRD2—alcohol dependence	0.00114	0.00625	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PDYN—alcohol dependence	0.00111	0.00609	CbGpPWpGaD
Regadenoson—Dizziness—Citalopram—alcohol dependence	0.00111	0.00156	CcSEcCtD
Regadenoson—Vomiting—Citalopram—alcohol dependence	0.00107	0.0015	CcSEcCtD
Regadenoson—Rash—Citalopram—alcohol dependence	0.00106	0.00149	CcSEcCtD
Regadenoson—Dermatitis—Citalopram—alcohol dependence	0.00106	0.00148	CcSEcCtD
Regadenoson—Headache—Citalopram—alcohol dependence	0.00105	0.00148	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—OPRD1—alcohol dependence	0.00105	0.00576	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—alcohol dependence	0.00105	0.00575	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CRHR1—alcohol dependence	0.00103	0.00566	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PDYN—alcohol dependence	0.00101	0.00553	CbGpPWpGaD
Regadenoson—Nausea—Citalopram—alcohol dependence	0.000999	0.0014	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CHRM2—alcohol dependence	0.000972	0.00532	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—AVP—alcohol dependence	0.000961	0.00526	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CRHR1—alcohol dependence	0.000939	0.00514	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—OPRK1—alcohol dependence	0.000926	0.00507	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—OPRM1—alcohol dependence	0.000892	0.00488	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CHRM2—alcohol dependence	0.000883	0.00483	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—alcohol dependence	0.000839	0.00459	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—NPY—alcohol dependence	0.000821	0.00449	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—OPRM1—alcohol dependence	0.00081	0.00443	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—HTR2A—alcohol dependence	0.0008	0.00438	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—EP300—alcohol dependence	0.000793	0.00434	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR1B—alcohol dependence	0.000792	0.00434	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CRH—alcohol dependence	0.000792	0.00434	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NPY—alcohol dependence	0.000746	0.00408	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HTR1B—alcohol dependence	0.000719	0.00394	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CRH—alcohol dependence	0.000719	0.00394	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—DRD4—alcohol dependence	0.000693	0.00379	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CNR1—alcohol dependence	0.000661	0.00362	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR7—alcohol dependence	0.000645	0.00353	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—DRD2—alcohol dependence	0.000645	0.00353	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—POMC—alcohol dependence	0.000639	0.00349	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—DRD4—alcohol dependence	0.000629	0.00344	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—OPRD1—alcohol dependence	0.000622	0.0034	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CNR1—alcohol dependence	0.0006	0.00329	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDYN—alcohol dependence	0.000596	0.00326	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—DRD2—alcohol dependence	0.000586	0.00321	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HTR7—alcohol dependence	0.000586	0.00321	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WASF2—alcohol dependence	0.000555	0.00303	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CRHR1—alcohol dependence	0.000555	0.00303	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AVP—alcohol dependence	0.000543	0.00297	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WASF1—alcohol dependence	0.000532	0.00291	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CHRM2—alcohol dependence	0.000521	0.00285	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AVP—alcohol dependence	0.000493	0.0027	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—OPRM1—alcohol dependence	0.000479	0.00262	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR2A—alcohol dependence	0.000452	0.00247	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NPY—alcohol dependence	0.000441	0.00241	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR1B—alcohol dependence	0.000425	0.00233	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CRH—alcohol dependence	0.000425	0.00233	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HTR2A—alcohol dependence	0.00041	0.00225	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DRD4—alcohol dependence	0.000372	0.00203	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—POMC—alcohol dependence	0.000361	0.00197	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CNR1—alcohol dependence	0.000355	0.00194	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DRD2—alcohol dependence	0.000346	0.00189	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR7—alcohol dependence	0.000346	0.00189	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—POMC—alcohol dependence	0.000328	0.00179	CbGpPWpGaD
Regadenoson—S-Adenosylmethionine—CYP2E1—alcohol dependence	0.000304	1	CrCbGaD
Regadenoson—ADORA2A—Signaling Pathways—AVP—alcohol dependence	0.000291	0.00159	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR2A—alcohol dependence	0.000242	0.00133	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—POMC—alcohol dependence	0.000194	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EP300—alcohol dependence	0.000128	0.000703	CbGpPWpGaD
